A director at Galapagos NV bought 62,273 shares at 28.810USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Galapagos Creates New Subscription Right Plan Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription right plan. On May 27, 2025, the Board of Directors of Galapagos approved “Subscription Right Plan 2025 (A)”, intended for personnel of the Company, within the framework of the authorized capital. Under this subscription right plan, 925,000 subscription rights were created, subject to acceptance, for senior management compensation p...
Galapagos creëert nieuw inschrijvingsrechtenplan Mechelen, België; 27 mei 2025, 22:30 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 925.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsrechtenplan. De Raad van Bestuur van Galapagos heeft op 27 mei 2025 “Inschrijvingsrechtenplan 2025 (A)”, bestemd voor personeel van de Vennootschap, goedgekeurd binnen het kader van het toegestaan kapitaal. Onder dit inschrijvingsrechtenplan werden 925.000 inschrijvingsrechten gecreëerd in het kader voor beloningen...
The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...
Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101 Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today announced that new data from our ongoing ATALANTA-1 Phase 1/2 study of GLPG5101 in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) have been accepted for oral presentations at the 2025 European Hematology Association (EHA) Congre...
Galapagos kondigt mondelinge presentaties aan tijdens EHA en ICML 2025 met veelbelovende nieuwe resultaten uit de ATALANTA-1 studie met CAR-T kandidaat GLPG5101 Mechelen, België; 14 mei 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG), een wereldwijd biotechnologiebedrijf dat zich toelegt op het veranderen van de resultaten voor patiënten door middel van levensveranderende wetenschap en innovatie, kondigde vandaag aan dat nieuwe gegevens uit haar lopende ATALANTA-1 fase 1/2-studie met GLPG5101 bij patiënten met recidief/refractair non-Hodgkin lymfoom (R/R NHL) geaccepteerd zijn voor ...
We had a 1-1 call with Galapagos' mgmt. including Henry Gosebruch, newly appointed CEO, and Jérôme Contamine, newly appointed chairman of the board following this morning's announcement regarding the re-evaluation of the proposed company split in favour of strategic alternatives for the cell therapy business. Our takeaway is this new approach leads to a similar outcome intended with the split, but through a smoother path. We summarise our key takeaways in this note.
Ekopak announces a €15m capital increase led by Alychlo, alongside major board and management changes. The transaction strengthens governance and liquidity, with Alychlo becoming the dominant shareholder. New projects and reaffirmed credit lines support continued growth under the WaaS model. The transaction, management, and board changes clearly exemplify the intention of reference shareholder Alychlo to re-start with a clean slate and mark a first step in rebuilding investor confidence . We mai...
Galapagos announced that the previously announced company split has been re-evaluated, and instead the company will explore strategic options for the cell therapy business. Henry Gosebruch has been appointed as CEO of Galapagos, replacing Paul Stoffels, effective immediately, and will lead the strategic evaluation process, while also focusing on building a new pipeline through business development. While we find the timing a bit of a surprise, we do note that this outcome could increase the cash...
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced hi...
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur Galapagos heroverweegt uitvoering van eerder aangekondigde splitsing naar aanleiding van ontwikkelingen in regelgeving en de markt Galapagos onderzoekt alle strategische alternatieven voor haar bestaande activiteiten, waaronder celtherapie, met de nadruk op het maximaliseren van de beschikbare middelen voor transformatieve business development transacties De heer Henry Gosebruch is door de Raad van Bestuur van Galapagos benoemd t...
A director at EXMAR NV bought 958,619 shares at 11.500EUR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.